| Literature DB >> 24011431 |
Limei Gao1, Menghao Cai, Wei Shen, Siwei Xiao, Xiangshan Zhou, Yuanxing Zhang.
Abstract
BACKGROUND: Polyketides are one of the most important classes of secondary metabolites and usually make good drugs. Currently, heterologous production of fungal polyketides for developing a high potential industrial application system with high production capacity and pharmaceutical feasibility was still at its infancy. Pichia pastoris is a highly successful system for the high production of a variety of heterologous proteins. In this work, we aim to develop a P. pastoris based in vivo fungal polyketide production system for first time and evaluate its feasibility for future industrial application.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24011431 PMCID: PMC3847973 DOI: 10.1186/1475-2859-12-77
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Figure 1The HPLC chromatogram of organic extracts from fermentation broth of strain GS115, GS115-ATX and GS115-NpgA-ATX. Samples preparation were described in the Section 6-MSA extraction and identification in Methods.
Figure 2The EI-MS identification of product 6-MSA by GS115-NpgA-ATX and transcription analysis of and . (A) EI-MS analysis of extract from GS115-NpgA-ATX. m/z, mass-to-charge ratio; (B) The 1HNMR analysis of extract from GS115-NpgA-ATX. Samples preparation were in the Section 6-MSA extraction and identification in Methods; (C) Lane 1–3: PCR using cDNA of wild type GS115 and primers 5AOX1/3AOX1, NpgA-F/R1 and BstpF/AtxR, respectively; Lane 4–6: PCR using GS115-NpgA-ATX cDNA and primers 5AOX1/3AOX1, NpgAF/ NpgAR1 and BstpF/AtxR, respectively; M: DNA marker Hind III. Gene transcription induced by 0.5% methanol for 24 h.
Figure 3Time profiles of GS115-NpgA-ATX in 5-L stirred-tank bioreactor fermentation. The first arrow (32 h) indicated the starting point of glycerol feeding; The second arrow (47 h) indicated the starting point of methanol induction. Culture conditions were shown in Methods.
Figure 4Transcription of and and western blot assay of PPtase induced by 0.5% methanol. (A) PCR with primers NpgA-HIS6-F/ NpgA-HIS6-R; (B) PCR with primers 1977 F/4088R. Lane 1: GS115-3.5 K-CT-SKL; Lane 2: GS115-NpgA-CT; Lane 3: GS115-NpgA-SKL-CT-SKL. (C) Western blot of PPtase. Lane1: GS115; Lane2: GS115-3.5 K-CT-SKL; Lane 3: GS115-NpgA-CT; Lane 4: GS115-NpgA-SKL-CT-SKL. The arrows indicates the positive bands of nucleic acids and proteins. Samples preparation and experimenal procedure were shown in the Section Transcription and western blot analysis in Methods.
Figure 5Nucleotide and amino acid sequences of ACP amd SDS-PAGE of PPTase and ACP and ACPm. (A) nucleotide and amino acid sequences ACP domain of citrinin polyketide synthase. The conserved serine at site 56 which marked by square frame was mutated by overlap PCR using primers mutant5/mutant3 to generate ACPm. (B) SDS-PAGE of PPTase expressed by GS115-NpgA-HIS6; (C) SDS-PAGE of ACP and ACPm expressed by E. coli BL21. Lane 1: Lysate supernatant of GS115-NpgA-HIS6; Lane 2: Flow-through fraction of GS115-NpgA-HIS6; Lane 3: Eluted protein of GS115-NpgA-HIS6; Lane 4: Lysate supernatant of wild type E. coli BL21 strain as negative control; Lane 5: Lysate supernatant of BL21-ACP; Lane 6: Lysate supernatant of BL21-ACPm. M: Protein marker. Protein purification were described in the Section Protein expression and purification in Methods. The arrows indicates the objective proteins.
Figure 6Fluorescent assay of ACP and ACPm that were fluorescently labelled. The KODAK In-vivo multispectral imaging systerm F was used for scanning. (A) Image parameter of 480 nm laser and 535 nm emission filter; (B) Image parameter of 580 nm laser and 670 nm emission filter; (C) Image of the same SDS-PAGE gel stained with Coomassie brilliant blue R-250. Lane 1: In vitro reaction containing Bodipy FL-CoA, PPtase and ACPm; Lane 2: In vitro reaction containing Bodipy-CoA, PPtase and ACP; Lane 3: In vitro reaction containing Alexa Fluor 647-CoA, PPtase and ACPm; Lane 4: In vitro reaction containing Alexa Fluor 647-CoA, PPtase and ACP. Protein preparation were described in Methods.
Primers used in this study
| NpgA-HIS6-F | GGA |
| GGAGGTGGATCTGTGCAAGACACATCAAGCGCAAG | |
| NpgA-HIS6-R | ATAAGAAT |
| 5AOX1 | GACTGGTTCCAATTGACAAGC |
| 3AOX1 | GCAAATGGCATTCTGACATCC |
| AcpF | CATG |
| AcpR | CCG |
| Mutant5 | TGGAATCGATGCGCTGATGAGCATG |
| Mutant3 | CATGCTCATCAGCGCATCGATTCCA |
| NpgAF | GGAATTC |
| NpgAR1 | ATGGGTACAGATCCTCTTCTGAGATGAGTTTTTGTTCGGATAGGCAATTACACACCCCAGTC |
| NpgAR2 | ATAAGAAT |
| AtxF | CGGGAATTCACCATGGAGGTACATGGAGATGAAGTG |
| AtxR | ATAAGAATGCGGCCGCCTTTCCCATCTTTTCCAAAAACCAT |
| BstpF | AACTGCAGAAGAATTCGGTTACCTGTACGTGGAAAAGGCTG |
| BstpR | AACTGCAGAAGGTAACCCACCTTGGGAGGCGGCTG |
| CTAF | TCC |
| CTAR | ATAAGAAT |
| CTBF | TCC |
| CTBR | GGAATTC |
| CTCF | CG |
| CTCR | CTAGCC |
| Citrinin-F2 | CCAT |
| Citrinin-R2 | GGGAATTC |
| NpgASR1 | ATGGGTACAGATCCTCTTCTGAGATGAGTTTTTGTTCGGATAGGCAATTACACACCCCAGTC |
| NpgASR2 | ATAAGAAT |
| 1977 F | TTCCTCAGCCCTACTGGTCAAT |
| 4088R | GCTGGGATGCGTCTTGATAACC |
a Restriction sites are underlined.
List of plasmids and strains in this work
| pET28a(+) | KanR; T7 promoter based | Novagen |
| pET28a-ACP | pET28a(+) derivative carrying | This study |
| pET28a-ACPm | pET28a(+) derivative carrying | This study |
| pESC-ATX | AmpR; | Moriguchi et al., 2006 |
| pPIC3.5 K | AmpR G418R; | Invitrogen |
| pPICZ B | ZeocinR ; | Invitrogen |
| pPIC3.5 K-NpgA | pPIC3.5 K derivative carrying | This study |
| pPICZ B-NpgA-HIS6 | pPICZ B derivative carrying | This study |
| pPICZ B-ATX | pPICZ B derivative carrying | This study |
| pPICZ B-CT-SKL | pPICZ B derivative carrying | This study |
| pPICZ B-CT | pPICZ B derivative carrying | This study |
| pPIC3.5 K-NpgA-SKL | pPIC3.5 K derivative carrying | This study |
| Reference | ||
| GS115 | Invitrogen | |
| GS115-NpgA-HIS6 | ZeocinR; GS115 with plasmid pPICZ B-NpgA-HIS6 | This study |
| GS115-ATX | ZeocinR; GS115 with plasmid pPICZ B-ATX | This study |
| GS115-NpgA | G418R; GS115 with plasmid pPIC3.5 K-NpgA | This study |
| GS115-NpgA-ATX | ZeocinR; G418R; GS115-NpgA with plasmid pPICZ B-ATX | This study |
| GS115-3.5 K | G418R; GS115 with pPIC3.5 K | This study |
| GS115-3.5 K-CT-SKL | ZeocinR; G418R; GS115-3.5 K with pPICZ B-CT-SKL | This study |
| GS115-NpgA-CT | ZeocinR; G418R; GS115-NpgA with plasmid pPICZ B-CT | This study |
| GS115-NpgA-SKL | G418R; GS115 with plasmid pPIC3.5 K-NpgA-SKL | This study |
| GS115-NpgA-CT-SKL | ZeocinR; G418R; GS115-NpgA with plasmid pPICZ B-CT-SKL | This study |
| GS115-NpgA-SKL-CT-SKL | ZeocinR; G418R; GS115-NpgA-SKL with plasmid pPICZ B-CT-SKL | This study |
| F’ [lacIq, Tn10(TetR)] | Invitrogen | |
| F– | Invitrogen | |
| BL21-ACP | KanR; BL21 with plasmid pET28a-ACP | This study |
| BL21-ACPm | KanR; BL21 with plasmid pET28a-ACPm | This study |